- Home
- / Precigen
Precigen
Stock Price
$0.8
2024-10-29
Market Capitalization
$246.6 M
2024-10-29
Revenue
$9.7 M
FY, 2025
Precigen Summary
Company Summary
- Overview
- Precigen (formerly known as Intrexon) is a biopharmaceutical company developing gene and cellular therapies for immuno-oncology, autoimmune, and infectious diseases. It offers the AdenoVerse gene delivery platform, the UltraVector DNA construction platform, and more.
- Type
- Public
- Status
- Active
- Founded
- 1998
- HQ
- Germantown, MD, US | view all locations
- Website
- https://precigen.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Steven Harasym, VP, Head of Investor Relations
Douglas E. Brough, SVP, Head of Research
Donald Lehr, Chief Legal Officer
LocationsView all
3 locations detected
Germantown, MD HQ
United States
20358 Seneca Meadows Pkwy
Sioux Center, IA
United States
Gent, Vlaanderen
Belgium
Industriepark Zwijnaarde 7C
Precigen Financials
Summary Financials
- Revenue (Q1, 2026)
- $23.3M
- Net income (Q1, 2026)
- ($7.9M)
- Cash (Q1, 2026)
- $7.5M
- EBIT (Q1, 2026)
- ($6.0M)
- Enterprise value
- $337.4M